Rapport Therapeutics Director Granted $240K in Stock Options, Vests in 2026

Director Steven M. Paul of Rapport Therapeutics received a stock option grant on June 17, 2025.

Rhea-AI Filing Summary

Director Steven M. Paul of Rapport Therapeutics received a stock option grant on June 17, 2025. The derivative securities transaction details include:

• Granted 21,850 stock options to purchase common stock
• Exercise price set at $10.95 per share
• Options expire on June 17, 2035
• Vesting occurs at earlier of:
  • June 17, 2026
  • Next Annual Meeting of Stockholders

The options are subject to continued service requirements and represent a standard director compensation grant. The transaction was reported via Form 4 filing executed by Troy Ignelzi as attorney-in-fact on June 18, 2025.

Insider Trade Summary

Grant/Award: 21,850 shares

Grant/Award 1 txn

Insider PAUL STEVEN M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	21,850	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,850 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did RAPP director Steven Paul receive on June 17, 2025?

According to the Form 4 filing, RAPP director Steven M. Paul received 21,850 stock options (Right to Buy) on June 17, 2025, with an exercise price of $10.95 per share.

When do Steven Paul's RAPP stock options vest?

The stock options will vest upon the earlier of two conditions: (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.

What is the exercise price and expiration date of RAPP director Paul's stock options?

The stock options have an exercise price of $10.95 per share and will expire on June 17, 2035, ten years from the grant date.

Who is Steven M. Paul at RAPP and what is his role?

According to the Form 4 filing, Steven M. Paul serves as a Director of Rapport Therapeutics, Inc. (RAPP). His business address is listed as 99 High Street, Suite 2100, Boston, MA 02110.

Did RAPP director Steven Paul purchase or sell any common stock directly in this transaction?

No, the Form 4 filing shows no direct purchases or sales of common stock. The only transaction reported was the grant of stock options as part of director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAUL STEVEN M

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.95	06/17/2025		A		21,850		(1)	06/17/2035	Common Stock	21,850	$0	21,850	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.